Erectile Dysfunction Drugs

Erectile Dysfunction (ED) Drugs Market (Drug - Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

  • Rep Id : TMRGL1550
  • Published On : Jun 2018
  • No. of Pages : 196
  • Category : Pharmaceutical

1. Preface
     1.1. Market Segmentation
     1.2. Key Research Objectives
     1.3. Research Highlights

2. Assumptions and Research Methodology
     2.1. Secondary Research Methodology
     2.2. Primary Research Methodology
     2.3. Analysis Research Methodology

3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Drug Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview

5. Market Outlook
     5.1. Market Dynamics
            5.1.1. Drivers
            5.1.2. Restraints
            5.1.3. Opportunity
            5.1.4. Opportunity Analysis
            5.1.5. Trends
     5.2. Global Erectile Dysfunction Market Analysis and Forecasts, 2016–2026
     5.3. Porter’s Five Forces Analysis
     5.4. Erectile Dysfunction Drugs Market Value Chain Analysis
     5.5. Pipeline Analysis
            5.5.1. Discovery
            5.5.2. Preclinical
            5.5.3. IND (Investigational New Drug)
            5.5.4. Phase I
            5.5.5. Phase I/II
            5.5.6. Phase II
            5.5.7. Phase III
            5.5.8. Pre-registration
     5.6. Global Erectile Dysfunction (ED) Drug Market Outlook

6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Drug
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value Forecast, by Drug, 2016–2026
            6.3.1. Viagra
            6.3.2. Cialis
            6.3.3. Staxyn/Levitra
            6.3.4. Stendra/Spedra
            6.3.5. Others
     6.4. Market Attractiveness, by Drug

7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Distribution Channel
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value Forecast, by Distribution Channel, 2016–2026
            7.3.1. Hospital Pharmacy
            7.3.2. Retail Pharmacy
            7.3.3. Online Pharmacy
     7.4. Market Attractiveness, by Distribution Channel

8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Region
     8.1. Key Findings
     8.2. Market Value Forecast, by Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Asia Pacific
            8.2.4. Latin America
            8.2.5. Middle East & Africa
     8.3. Market Attractiveness, by Country/Region

9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. Market Value Forecast, by Drug, 2016–2026
            9.2.1. Viagra
            9.2.2. Cialis
            9.2.3. Staxyn/Levitra
            9.2.4. Stendra/Spedra
            9.2.5. Others
     9.3. Market Value Forecast, by Distribution Channel, 2016–2026
            9.3.1. Hospital Pharmacy
            9.3.2. Retail Pharmacy
            9.3.3. Online Pharmacy
     9.4. Market Value Forecast, by Country, 2016–2026
            9.4.1. U.S.
            9.4.2. Canada

10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Market Value Forecast, by Drug, 2016–2026
            10.2.1. Viagra
            10.2.2. Cialis
            10.2.3. Staxyn/Levitra
            10.2.4. Stendra/Spedra
            10.2.5. Others
     10.3. Market Value Forecast, by Distribution Channel, 2016–2026
            10.3.1. Hospital Pharmacy
            10.3.2. Retail Pharmacy
            10.3.3. Online Pharmacy
     10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. France
            10.4.4. Spain
            10.4.5. Italy
            10.4.6. Rest of Europe

11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2.Market Value Forecast, by Drug, 2016–2026
            11.2.1. Viagra
            11.2.2. Cialis
            11.2.3. Staxyn/Levitra
            11.2.4. Stendra/Spedra
            11.2.5. Others
     11.3.Market Value Forecast, by Distribution Channel, 2016–2026
            11.3.1. Hospital Pharmacy
            11.3.2. Retail Pharmacy
            11.3.3. Online Pharmacy
     11.4.Market Value Forecast, by Country/Sub-region, 2016–2026
            11.4.1. China
            11.4.2. Japan
            11.4.3. India
            11.4.4. Australia & New Zealand
            11.4.5. Rest of Asia Pacific

12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2.Market Value Forecast, by Drug, 2016–2026
            12.2.1. Viagra
            12.2.2. Cialis
            12.2.3. Staxyn/Levitra
            12.2.4. Stendra/Spedra
            12.2.5. Others
     12.3.Market Value Forecast, by Distribution Channel, 2016–2026
            12.3.1. Hospital Pharmacy
            12.3.2. Retail Pharmacy
            12.3.3. Online Pharmacy
     12.4.Market Value Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of Latin America

13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2.Market Value Forecast, by Drug, 2016–2026
            13.2.1. Viagra
            13.2.2. Cialis
            13.2.3. Staxyn/Levitra
            13.2.4. Stendra/Spedra
            13.2.5. Others
     13.3.Market Value Forecast, by Distribution Channel, 2016–2026
            13.3.1. Hospital Pharmacy
            13.3.2. Retail Pharmacy
            13.3.3. Online Pharmacy
     13.4.Market Value Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. South Africa
            13.4.3. Rest of Middle East & Africa

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Market Share Analysis, by Company (2017)
     14.3. Competitive Business Strategies
     14.4. Company Profiles
            14.4.1. Pfizer, Inc.
                     14.4.1.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.1.2. Product Portfolio
                     14.4.1.3. SWOT Analysis
                     14.4.1.4. Strategic Overview
            14.4.2. Dong-A ST Co., Ltd.
                     14.4.2.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.2.2. Product Portfolio
                     14.4.2.3. SWOT Analysis
                     14.4.2.4. Strategic Overview
            14.4.3. Eli Lilly and Company
                     14.4.3.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.3.2. Product Portfolio
                     14.4.3.3. SWOT Analysis
                     14.4.3.4. Strategic Overview
            14.4.4. Bayer AG
                     14.4.4.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.4.2. Product Portfolio
                     14.4.4.3. SWOT Analysis
                     14.4.4.4. Strategic Overview
            14.4.5. VIVUS, INC.
                     14.4.5.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.5.2. Product Portfolio
                     14.4.5.3. SWOT Analysis
                     14.4.5.4. Strategic Overview
            14.4.6. SK chemicals
                     14.4.6.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.6.2. Product Portfolio
                     14.4.6.3. SWOT Analysis
                     14.4.6.4. Strategic Overview
            14.4.7. Meda Pharmaceuticals Inc.
                     14.4.7.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.7.2. Product Portfolio
                     14.4.7.3. SWOT Analysis
                     14.4.7.4. Strategic Overview
            14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.
                     14.4.8.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.8.2. Product Portfolio
                     14.4.8.3. SWOT Analysis
                     14.4.8.4. Strategic Overview
            14.4.9. Apricus Biosciences, Inc.
                     14.4.9.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.9.2. Product Portfolio
                     14.4.9.3. SWOT Analysis
                     14.4.9.4. Strategic Overview
            14.4.10. Teva Pharmaceutical Industries Ltd.
                     14.4.10.1. Company Overview (HQ, Business Segments, Employee)
                     14.4.10.2. Product Portfolio
                     14.4.10.3. SWOT Analysis
                     14.4.10.4. Strategic Overview

List of Tables:

Table 01: Global Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 03: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 04: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 05: North America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 06: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 07: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 08: Europe Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 9: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 11: Asia Pacific Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 12: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Latin America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 18: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 19: Pfizer, Inc. Products Offered
Table 20: Pfizer, Inc. Recent Developments
Table 21: Dong-A ST Co., Ltd. Products Offered
Table 22: Dong-A ST Co., Ltd. Recent Developments
Table 23: Eli Lilly and Company Products Offered
Table 24: Eli Lilly and Company Recent Developments
Table 25: Bayer AG Products Offered
Table 26: Bayer AG Recent Developments
Table 27: VIVUS, INC. Ltd. Products Offered
Table 28: VIVUS, INC. Recent Developments
Table 29: SK chemicals Products Offered
Table 30: SK chemicals Recent Developments
Table 31: Meda Pharmaceuticals Inc. Products Offered
Table 32: Meda Pharmaceuticals Inc. Recent Developments
Table 33: Cristalia Produtos Quimicos Farmaceuticos Ltda. Products Offered
Table 34: Cristalia Produtos Quimicos Farmaceuticos Ltda. Recent Developments
Table 35: Apricus Biosciences, Inc.  Products Offered
Table 36: Apricus Biosciences, Inc. Recent Developments
Table 37: Teva Pharmaceutical Industries Ltd. Products Offered

List of Figures:

Figure 01: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, 2016–2026
Figure 02: Market Value Share, by Drug Class (2017)
Figure 04: Market Value Share, by Distribution Channel (2017)
Figure 05: Market Value Share, by Region (2017)
Figure 06: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
Figure 07: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Viagra, 2016–2026
Figure 08: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Cialis, 2016–2026
Figure 9: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Staxyn/Levitra, 2016–2026
Figure 10: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Stendra/Spedra, 2016–2026
Figure 11: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by others, 2016–2026
Figure 12: Global Erectile Dysfunction (ED) Drug Market Value Share Analysis, by Distribution channel, 2017 and 2026
Figure 13: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2016–2026
Figure 14: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2016–2026
Figure 15: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2016-2026
Figure 16: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Region, 2017 and 2026 
Figure 17: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2026
Figure 18: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country, 2017 and 2026
Figure 19: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
Figure 20: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2026
Figure 21: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 22: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 23: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
Figure 24: Europe Erectile Dysfunction (ED) Drugs Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 25: Asia Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 26: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 27: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 28: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 29: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 30: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 31: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 32: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 33: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
Figure 34: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 35: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
Figure 36: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 37: Global Erectile Dysfunction (ED) Drugs Market Share Analysis, by Company (2017)
Figure 38: Pfizer, Inc. Breakdown of Net Sales, by Region, 2016
Figure 39: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 40: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 41: Dong-A ST Co., Ltd. Breakdown of Net Sales, by Businesses Segment
Figure 42: Dong-A ST Co., Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
Figure 43: Dong-A ST Co., Ltd. R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 44: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 45: Eli Lilly and Company R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 46: Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2016
Figure 47: Eli Lilly and Company Breakdown of Net Sales, (by Endocrinology Level), 2016
Figure 48: Bayer AG Breakdown of Net Sales, by Region, 2017
Figure 49: Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017
Figure 50: Bayer AG R&D Intensity and Net Income (US$ Mn) – Company Level, 2016–2017
Figure 51: VIVUS, INC. R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 52: VIVUS, INC. Breakdown of Revenue, by Operation (Company Level), 2017
Figure 53: VIVUS, INC. Breakdown of Research and Development Expenses, 2017
Figure 54: SK chemicals Consolidated Balance Sheet (US$ Bn), 2016
Figure 55: SK chemicals Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017
Figure 56: SK chemicals R&D Intensity and Net Income (US$ Mn) – Company Level, 2014–2016
Figure 57: Meda Pharmaceuticals Inc. Breakdown of Net Sales, by Region, 2015
Figure 58: Meda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2011–2015
Figure 59: Meda Pharmaceuticals Inc. Selling, Medicine &business development and administrative expenses (US$ Mn) – Company Level, 2014–2015
Figure 60: Apricus Biosciences, Inc. Breakdown of Net Sales, by Region, 2017
Figure 61: Apricus Biosciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 62: Apricus Biosciences, Inc. R&D and General & administrative (US$ Mn) – Company Level, 2015–2016
Figure 63: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 64: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
Figure 65: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2016
Figure 66: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2016

.